Baseline characteristics of the MTX population and total trial participants. Values are n (%) or median (IQR).
| Characteristics | MTX Population, n = 188 | Total Trial Participants, n = 206 |
|---|---|---|
| Male | 100 (53.2) | 108 (52.4) |
| Age, yrs | 44.5 (37.0–52.0) | 45 (38–53) |
| White ethnicity | 171 (91.0) | 188 (91.3) |
| No. swollen joints, 0–66 | 5.0 (3.0–9.0) | 5.0 (2.0–9.0) |
| No. tender joints, 0–68 | 9.0 (3.5–19.0 | 9.0 (4.0–18.0) |
| CRP, mg/dl | 6.6 (5.0–20.0) | 6.7 (5.0–18.2) |
| RF-negative | 177 (94.1) | 195 (94.7) |
| CCP-negative | 158 (84.0) | 172 (83.5) |
| EMS | 168 (89.4) | 184 (89.3) |
| EMS duration, hours | 1.0 (0.0–2.0) | 1.0 (0.5–2.0) |
| Arthritis pattern | ||
| Polyarthritis, ≥ 5 joints | 135 (71.8) | 146 (70.9) |
| Oligoarthritis, < 5 joints | 53 (28.2) | 60 (29.1) |
| DIP disease | 41 (21.8) | 45 (21.8) |
| Axial involvement | 42 (22.3) | 43 (20.9) |
| Arthritis mutilans | 0 (0.0) | 0 (0.0) |
| CASPAR criteria met, score ≥ 3 | 172 (91.5) | 188 (91.3) |
| CASPAR score ≥ 2 | 184 (97.9) | 202 (98.1) |
| Current psoriasis | 159 (84.6) | 174 (84.5) |
| PASI score, all patients | 2.0 (0.6–4.2) | 1.9 (0.6–4.2) |
| PASI score, condition at baseline | 2.6 (1.2–4.7) | 2.6 (1.2–4.8) |
| Current enthesitis | 148 (78.7) | 162 (78.6) |
| Enthesitis score, all patients | 2.0 (1.0–6.0) | 2.0 (1.0–6.0) |
| Enthesitis score, condition at baseline | 4.0 (2.0–7.0) | 4.0 (2.0–7.0) |
| Current dactylitis | 59 (31.4) | 62 (30.1) |
| Dactylitis score, all patients | 0.0 (0.0–15.8) | 0.0 (0.0–13.0) |
| Dactylitis score, condition at baseline | 38.0 (20.0–105.0) | 37.0 (19.0–96.0) |
| Current nail disease | 117 (62.2) | 124 (60.2) |
| mNAPSI score, all patients | 2.0 (0.0–11.8) | 2.0 (0.0–10.0) |
| mNAPSI score, condition at baseline | 8.0 (2.0–20.0) | 8.0 (2.0–19.0) |
MTX: methotrexate; IQR: interquartile range; CRP: C-reactive protein; RF: rheumatoid factor; CCP: cyclic citrullinated peptide antibodies; EMS: early morning stiffness; DIP: distal interphalangeal joint; CASPAR: the ClASsification of Psoriatic ARthritis study; PASI: Psoriasis Area and Severity Index; mNAPSI: modified Nail Psoriasis Severity Index.